The US Food and Drug Administration (FDA) approved Koselugo (selumetinib) for the treatment of neurofibromatosis type 1 (NF1) for children ages 2-17 who have plexiform neurofibromas (PN) that cause symptoms and cannot be completely removed by surgery, or for which surgery is not advisable due to potential unwanted side effects with surgery.

ASICS Falmouth Road Race 2025